A University of Iowa (UI) spin-out company developing a drug-delivering mechanism to prevent the onset of post-traumatic osteoarthritis recently earned second place—and $25,000—in the 2019 John Pappajohn Iowa Entrepreneurial Venture Competition.
A system designed by a University of Iowa ophthalmologist that uses artificial intelligence (AI) to detect diabetic retinopathy without a person interpreting the results earned Food and Drug Administration (FDA) authorization in April, following a clinical trial in primary care offices. Results of that study were published Aug. 28 online in Nature Digital Medicine, offering the first look at data that led to FDA clearance for IDx-DR, the first medical device that uses AI for the autonomous detection of diabetic retinopathy.
University of Iowa spinout company Voxello, which develops technologies that allow hospitalized patients to overcome communication barriers, recently received three grants to help advance its research and development.
Having clear and up-to-date protocols and policies around intellectual property (IP) is critically important for moving discovery at the University of Iowa forward. It ensures that inventions by faculty and staff are clearly identified, adequately protected, and leveraged in a way that benefits the inventor, the university, and the public—should the IP eventually translate into a commercial product, service, or company.
University of Iowa faculty interested in learning how to translate their research into a device, service, or business are invited to apply to the UI’s Faculty Innovators Workshop, a four-week version of the UI Venture School designed to help participants develop marketable ideas and accelerate the startup process.
The next cohort starts Oct. 25, and workshop sessions run from 5:30 to 9 p.m. Oct. 25, Nov. 1, Nov. 9, and Nov. 15 in Room 1459 of the Pappajohn Biomedical Discovery Building.